AHRQ Examines Impact of Payment Policies on Clinical Trials
AHRQ Examines Impact of Payment Policies on Clinical Trials
The Agency for Healthcare Research and Quality (AHRQ) has released a draft paper examining the impact of changes in payment policies on clinical trials. The report discusses the relationship between third-party payments and the recruitment and retention of participants in clinical trials. Among the conclusions of the report: payment policies do affect evidence development in that their impact on clinical trial enrollment results in slower accrual, longer time to complete studies, and the occasional early termination of a study due to a lack of participation. Further, the reports suggest that better coordination among government agencies and between government, third-party payors, sponsors, and trial sites is necessary. Comments on the report are due Jan. 23.
Information: Go to http://www.ahrq.gov/clinic/ta/paypolicy/paypolicy.pdf
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
